Pacira BioSciences Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 1/6
Pacira BioSciences şirketinin kazançları yıllık ortalama -55.6% oranında azalırken, Pharmaceuticals sektörünün kazançları yıllık 9.7% oranında artan oldu. Gelirler yıllık ortalama 7.4% oranında artan oldu. Pacira BioSciences şirketinin öz sermaye getirisi 0.8% olup, net marjı 0.7% dir.
Anahtar bilgiler
-55.58%
Kazanç büyüme oranı
-56.43%
EPS büyüme oranı
| Pharmaceuticals Sektör Büyümesi | 5.95% |
| Gelir büyüme oranı | 7.36% |
| Özkaynak getirisi | 0.79% |
| Net Marj | 0.70% |
| Son Kazanç Güncellemesi | 31 Mar 2026 |
Yakın geçmiş performans güncellemeleri
Recent updates
Seeking Alpha • May 19
Pacira BioSciences: Exparel Still Supports My Original Bull Case
Summary PCRX remains a commercial non-opioid pain company built around Exparel, Zilretta, and Iovera. That’s why I think the most important catalysts for this stock, for better or worse, will be its upcoming 2026 pipeline readouts. But I reckon that PCRX’s overdependence on Exparel remains a factor worth considering, aside from other inherent biotech risks like patents and reimbursement policies, among others. Fortunately, PCRX’s recent pullback actually offers a discount on a relatively improved company compared to the first time I covered it. As such, I reiterate my “Buy” on PCRX. Read the full article on Seeking Alpha
Anlatı Güncellemesi • May 01
PCRX: Real World Procedure Data Will Support Future Upside Repricing
Analysts nudged their price target on Pacira BioSciences up by $2, citing slightly stronger modeled revenue growth of 17.50% and an 8.33% profit margin outlook, supported by recent real world data updates and mixed but active coverage on the stock. Analyst Commentary Recent research has been mixed, but the latest commentary highlights that bullish analysts are still finding reasons to lean constructive on Pacira BioSciences, especially around the updated revenue growth and margin framework that underpins the new price target.
Anlatı Güncellemesi • Apr 16
PCRX: Real World Hip Data And Activist Pressure Will Shape Outlook
Analysts have reduced their Pacira BioSciences price target by $2, citing updated real world data in hip arthroplasty and revisions to growth, margin, and future P/E assumptions. Analyst Commentary Bearish analysts are flagging that updated real world hip arthroplasty data has introduced more uncertainty into Pacira BioSciences' outlook, leading to more cautious assumptions around growth, margin profile, and future P/E levels.Anlatı Güncellemesi • Apr 01
PCRX: Higher 2026 Outlook And Activist Pressure Will Unlock Future Upside
Analysts have trimmed their Pacira BioSciences price target by $2, citing updated assumptions around faster revenue growth, a lower profit margin outlook, and a higher future P/E multiple. Analyst Commentary Despite the modest trim to the headline price target, bullish analysts see the updated assumptions as a way to reset expectations while keeping a constructive view on Pacira BioSciences.Anlatı Güncellemesi • Mar 17
PCRX: Future Outlook Weighs Activist Board Push Against Asia Licensing Upside
Analysts have reaffirmed their $22.00 price target for Pacira BioSciences, noting small adjustments to revenue growth, profit margin assumptions, and a slightly lower future P/E multiple to reflect updated expectations for the company’s earnings profile. What's in the News DOMA Perpetual Capital Management nominated three director candidates for the 2026 annual meeting and called for the immediate replacement of CEO Frank Lee, the appointment of an interim CEO, and a formal sale process for the business (Investor activism, March 12, 2026).Anlatı Güncellemesi • Mar 03
PCRX: Future Outlook Balances Asia Partnership Progress With Activist Pressure
Analysts have trimmed their price target on Pacira BioSciences from $24 to $22, reflecting updated assumptions that include a higher discount rate, more conservative revenue expectations, and lower projected profit margins, partly offset by a slightly higher future P/E multiple. What's in the News Issued full year 2026 earnings guidance, with total revenue expected in a range of $745 million to $770 million.Anlatı Güncellemesi • Feb 17
PCRX: Asia Partnership Will Drive Future Upside Potential
Analysts have kept their $38.00 price target for Pacira BioSciences steady, with only small tweaks to assumptions around revenue growth, profit margins and future P/E that support this unchanged view. What's in the News Pacira BioSciences entered an agreement with LG Chem that gives LG Chem exclusive rights to commercialize EXPAREL in select Asia Pacific markets.Anlatı Güncellemesi • Feb 02
PCRX: Asia Partnerships And Pipeline Progress Will Drive Future Upside Potential
Analysts have reiterated a US$38.00 price target for Pacira BioSciences, citing slightly updated assumptions for revenue growth, profit margin, and future P/E that collectively leave their overall valuation view unchanged. What's in the News Pacira entered an agreement with LG Chem, giving LG Chem exclusive rights to commercialize EXPAREL in select Asia Pacific markets, with Pacira receiving an upfront payment, transfer price, and tiered royalties while LG Chem handles regulatory filings in South Korea and Thailand within six months (Client Announcements).Anlatı Güncellemesi • Jan 19
PCRX: Asia Partnership And Pipeline Advances Will Drive Future Upside Potential
Narrative Update Analysts have kept their price target for Pacira BioSciences broadly steady around $38.00, citing slightly higher modeled revenue growth, a modestly lower profit margin outlook, and a similar forward P/E assumption. What’s in the News Pacira entered an agreement with LG Chem, granting LG Chem exclusive rights to commercialize EXPAREL in select Asia Pacific markets.Analiz Makalesi • Jan 17
Revenues Working Against Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Share Price Following 28% Dive
Pacira BioSciences, Inc. ( NASDAQ:PCRX ) shareholders won't be pleased to see that the share price has had a very rough...Anlatı Güncellemesi • Jan 05
PCRX: Share Buybacks And Activist Pressure Will Support Future Upside Potential
Analysts have kept their fair value estimate for Pacira BioSciences steady at $38.00. The latest price target is grounded in updated assumptions for slightly different revenue growth, profit margin expectations, and a higher future P/E multiple.Anlatı Güncellemesi • Dec 14
PCRX: Activist Pressure And Share Buybacks Will Unlock Future Upside Potential
Analysts have modestly raised their price target on Pacira BioSciences to $38.00 from $36.00, citing expectations for slightly stronger long term profitability despite a somewhat more conservative revenue growth outlook and valuation multiple. What's in the News Activist investor DOMA Perpetual Capital Management sent a letter to Pacira's board urging the company to hire bankers and pursue a full sale process, citing persistent underperformance and overspending (Key Developments).Analiz Makalesi • Nov 13
Pacira BioSciences' (NASDAQ:PCRX) Strong Earnings Are Of Good Quality
When companies post strong earnings, the stock generally performs well, just like Pacira BioSciences, Inc.'s...
Anlatı Güncellemesi • Aug 17
Policy Changes And Partnerships Will Expand Ambulatory Market Reach
The slight decrease in consensus revenue growth expectations and a lower future P/E multiple have led analysts to reduce their fair value estimate for Pacira BioSciences from $30.60 to $29.00. What's in the News Pacira completed a $50.04 million buyback, repurchasing 1,955,589 shares (4.23%) under its May 2025 authorization and previously completed a $25 million buyback (837,240 shares, 1.8%) under its May 2024 authorization.Analiz Makalesi • Jun 11
Pacira BioSciences (NASDAQ:PCRX) Seems To Use Debt Quite Sensibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Apr 09
Pacira BioSciences Remains A 'Buy' For Pain Management With The NOPAIN Act
Summary PCRX focuses on non-opioid pain management with Exparel, Zilretta, and iovera, delivering targeted pain relief with fewer side effects. A key secular tailwind for them comes from the NOPAIN Act, which creates separate reimbursement and grows access to non-opioid therapies. Also, PCRX’s PCRX-201 is a promising new gene therapy for knee osteoarthritis, which so far has shown promising results and targets a sizeable TAM. I also like how PCRX reached important patent settlements that secure its competitive prospects with Exparel’s exclusivity until 2030. In my view, PCRX remains undervalued at these levels, which is why I consider it a “Buy” despite its inherent biotech risks. Read the full article on Seeking AlphaAnaliz Makalesi • Apr 07
Pacira BioSciences, Inc. (NASDAQ:PCRX) Looks Inexpensive But Perhaps Not Attractive Enough
You may think that with a price-to-sales (or "P/S") ratio of 1.5x Pacira BioSciences, Inc. ( NASDAQ:PCRX ) is a stock...Seeking Alpha • Mar 14
Pacira BioSciences: Back On An Uptrend After Positive Developments
Summary Pacira BioSciences, Inc.'s stock is up 33% since my last “Buy” rating, driven by strategic moves and market overreaction correction. The company has secured a new patent for its lead pain therapeutic, Exparel, delaying generic market entrants, and potentially protecting its market share until mid-next decade. Vertex's Journavx launch may boost awareness for non-opioid pain relief, benefiting Pacira's Exparel under the NOPAIN Act. Pacira's new five-point plan aims for growth, profitability, and pipeline expansion, positioning it for potential blockbuster revenue and market leadership. The positive steps PCRX has taken since my last note means there is no change to my “buy” thesis. Read the full article on Seeking AlphaAnaliz Makalesi • Jan 30
Pacira BioSciences (NASDAQ:PCRX) Has A Rock Solid Balance Sheet
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analiz Makalesi • Jan 03
Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Low P/S No Reason For Excitement
You may think that with a price-to-sales (or "P/S") ratio of 1.2x Pacira BioSciences, Inc. ( NASDAQ:PCRX ) is a stock...Seeking Alpha • Nov 25
Pacira BioSciences: Not Done Yet Despite Devastating Share Price Losses
Summary Pacira BioSciences markets and sells EXPAREL, a non-opioid pain relief therapy. The drug drives revenues of >$500m per annum, but a new generic version has been approved, while Pharma giant Vertex is close to having a similar drug approved. Pacira's share price has plummeted from >$80 in mid-2022 to ~$18 today, as the market sees little growth in the business and notes the competitive threats. The market may be a little too pessimistic - Vertex's drug is unproven in the market while generics may be held off for many more years. EXPAREL's peak years may still be ahead - PCRX stock could recoup some deserved value if it can share positive Q4 earnings, update on legal matters, and keep developing its pipeline. Read the full article on Seeking Alpha
Yeni Anlatı • Sep 24
EXPAREL's Calculated Expansion And Innovative R&D Bolster Market Dominance Amidst Challenges
Expanding EXPAREL utilization in outpatient settings and through GPO partnerships aims to enhance revenue by increasing market penetration and affordability.Analiz Makalesi • Sep 06
Pacira BioSciences, Inc. (NASDAQ:PCRX) Not Doing Enough For Some Investors As Its Shares Slump 34%
To the annoyance of some shareholders, Pacira BioSciences, Inc. ( NASDAQ:PCRX ) shares are down a considerable 34% in...Analiz Makalesi • Jul 23
Little Excitement Around Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Revenues As Shares Take 29% Pounding
Pacira BioSciences, Inc. ( NASDAQ:PCRX ) shareholders that were waiting for something to happen have been dealt a blow...Gelir ve Gider Dağılımı
Gelir ve Gider Dağılımı
Pacira BioSciences nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 31 Mar 26 | 735 | 5 | 376 | 120 |
| 31 Dec 25 | 726 | 7 | 369 | 117 |
| 30 Sep 25 | 717 | 21 | 347 | 104 |
| 30 Jun 25 | 706 | -127 | 329 | 97 |
| 31 Mar 25 | 703 | -104 | 309 | 89 |
| 31 Dec 24 | 701 | -100 | 294 | 82 |
| 30 Sep 24 | 695 | -91 | 280 | 77 |
| 30 Jun 24 | 690 | 64 | 274 | 79 |
| 31 Mar 24 | 682 | 70 | 271 | 77 |
| 31 Dec 23 | 675 | 42 | 269 | 76 |
| 30 Sep 23 | 666 | 7 | 268 | 74 |
| 30 Jun 23 | 669 | -5 | 261 | 73 |
| 31 Mar 23 | 669 | -10 | 261 | 80 |
| 31 Dec 22 | 667 | 16 | 255 | 85 |
| 30 Sep 22 | 654 | 21 | 243 | 83 |
| 30 Jun 22 | 614 | 39 | 229 | 75 |
| 31 Mar 22 | 580 | 38 | 215 | 61 |
| 31 Dec 21 | 542 | 42 | 199 | 56 |
| 30 Sep 21 | 513 | 62 | 200 | 55 |
| 30 Jun 21 | 503 | 174 | 205 | 58 |
| 31 Mar 21 | 443 | 148 | 197 | 59 |
| 31 Dec 20 | 430 | 146 | 194 | 59 |
| 30 Sep 20 | 421 | 126 | 197 | 64 |
| 30 Jun 20 | 408 | -10 | 195 | 69 |
| 31 Mar 20 | 435 | 0 | 200 | 74 |
| 31 Dec 19 | 421 | -11 | 201 | 72 |
| 30 Sep 19 | 394 | 2 | 191 | 52 |
| 30 Jun 19 | 372 | 8 | 185 | 32 |
| 31 Mar 19 | 354 | 7 | 180 | 14 |
| 31 Dec 18 | 337 | 0 | 177 | 56 |
| 30 Sep 18 | 321 | -4 | 172 | 0 |
| 30 Jun 18 | 305 | -11 | 168 | 0 |
| 31 Mar 18 | 292 | -33 | 164 | 0 |
| 31 Dec 17 | 287 | -43 | 161 | 0 |
| 30 Sep 17 | 280 | -51 | 157 | 0 |
| 30 Jun 17 | 281 | -66 | 153 | 0 |
| 31 Mar 17 | 280 | -54 | 157 | 0 |
| 31 Dec 16 | 276 | -38 | 153 | 0 |
| 30 Sep 16 | 273 | -36 | 155 | 0 |
| 30 Jun 16 | 267 | -11 | 154 | 0 |
| 31 Mar 16 | 256 | -3 | 146 | 0 |
| 31 Dec 15 | 249 | 2 | 139 | 0 |
| 30 Sep 15 | 241 | 10 | 133 | 0 |
| 30 Jun 15 | 231 | 4 | 125 | 0 |
Kaliteli Kazançlar: PCRX büyük bir tek seferlik zarar ile $7.0M, 31st March, 2026 tarihine ait son 12 aylık mali sonuçları etkiliyor.
Büyüyen Kar Marjı: PCRX geçmişte karlı hale geldi.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: PCRX şirketinin kazançları son 5 yılda yılda 55.6% oranında azaldı.
Büyüme Hızlandırma: PCRX son bir yılda karlı hale geldi, bu da kazanç büyüme oranının 5 yıllık ortalamayla karşılaştırılmasını zorlaştırıyor.
Kazançlar vs. Sektör: PCRX son bir yılda karlı hale geldi ve bu durum, geçmiş yıl kazanç büyümesinin Pharmaceuticals sektörüyle ( -5% ) karşılaştırılmasını zorlaştırıyor.
Özkaynak Getirisi
Yüksek ROE: PCRX 'nin Özsermaye Getirisi ( 0.8% ) düşük olarak değerlendiriliyor.
Varlık Getirisi
Kullanılan Sermaye Getirisi
Geçmişte güçlü performans gösteren şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/22 10:23 |
| Gün Sonu Hisse Fiyatı | 2026/05/22 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Pacira BioSciences, Inc. 29 Bu analistlerden 6, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Jenna Davidner | Barclays |
| Anita Dushyanth | Berenberg |
| Gary Nachman | BMO Capital Markets Equity Research |